# Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 3, 2025

## HEL 92.1.7

RRID:CVCL_2481
Type: Cell Line

### Proper Citation

(RRID:CVCL_2481)

### Cell Line Information

**URL:** https://web.expasy.org/cellosaurus/CVCL_2481

**Proper Citation:** (RRID:CVCL_2481)

**Sex:** Male

**Defining Citation:** PMID:20215515, PMID:22460905, PMID:30285677, PMID:30894373, PMID:31068700, PMID:31978347

**Comments:** Donor information: Originally the patient was suffering from Hodgkin lymphoma., Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Deep quantitative proteome analysis., Omics: Deep exome analysis., Population: Caucasian., Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981)., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

**Category:** Cancer cell line

**Name:** HEL 92.1.7

**Synonyms:** HEL92.1.7, HEL-92.1.7, HEL-92-1-7, HEL-92_1_7, HEL-92, HEL9217

**Cross References:** BTO:BTO_0003320, CLO:CLO_0003682, CLO:CLO_0003683, EFO:EFO_0002193, CLDB:cl5067, CLDB:cl7132, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2770, ATCC:TIB-180, BCRC:60370, BCRJ:0308, BioSample:SAMN10987842, cancercelllines:CVCL_2481, Cell_Model_Passport:SIDM00593, ChEMBL-Cells:CHEMBL4295457, ChEMBL-Targets:CHEMBL4296425, CLS:300462, Cosmic:683543, Cosmic:976723, DepMap:ACH-000005, ECACC:92111706, GEO:GSM887076, GEO:GSM888146, GEO:GSM1374526, GEO:GSM1374527, IARC_TP53:21369, ICLC:HTL03002, IGRhCellID:HEL9217,

LiGeA:CCLE_672, LINCS_LDP:LCL-1076, Lonza:1042, PharmacoDB:HEL92_1_7_535_2019, Progenetix:CVCL_2481, PubChem_Cell_line:CVCL_2481, Wikidata:Q54882504

**ID:** CVCL_2481

**Record Creation Time:** 20250131T200356+0000

**Record Last Update:** 20250131T201611+0000

## Ratings and Alerts

No rating or validation information has been found for HEL 92.1.7.

No alerts have been found for HEL 92.1.7.

## Data and Source Information

**Source:** Cellosaurus

## Usage and Citation Metrics

We found 21 mentions in open access literature.

**Listed below are recent publications.** The full list is available at FDI Lab - SciCrunch.org.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell chemical biology, 31(7), 1247.

Blöchl C, et al. (2023) Transcriptionally imprinted glycomic signatures of acute myeloid leukemia. Cell & bioscience, 13(1), 31.

Nicosia L, et al. (2023) Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies. Cancer cell, 41(12), 2136.

Saleiro D, et al. (2023) Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells. Cancer research communications, 3(5), 943.

Wei TT, et al. (2022) Cannabinoid receptor 1 antagonist genistein attenuates marijuana-induced vascular inflammation. Cell, 185(10), 1676.

Roversi FM, et al. (2022) Novel inhibitor of hematopoietic cell kinase as a potential therapeutic agent for acute myeloid leukemia. Cancer immunology, immunotherapy : CII, 71(8), 1909.

Yang BH, et al. (2022) Epigenetics-Associated Risk Reduction of Hematologic Neoplasms in

a Nationwide Cohort Study: The Chemopreventive and Therapeutic Efficacy of Hydralazine. Frontiers in oncology, 12, 809014.

Polyanskaya SA, et al. (2022) SCP4-STK35/PDIK1L complex is a dual phospho-catalytic signaling dependency in acute myeloid leukemia. Cell reports, 38(2), 110233.

Cao Z, et al. (2021) ZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency. Molecular cell, 81(17), 3604.

Takao S, et al. (2021) Convergent organization of aberrant MYB complex controls oncogenic gene expression in acute myeloid leukemia. eLife, 10.

Jin S, et al. (2020) 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(13), 3371.

Morita K, et al. (2020) Allosteric Activators of Protein Phosphatase 2A Display Broad Antitumor Activity Mediated by Dephosphorylation of MYBL2. Cell, 181(3), 702.

Gier RA, et al. (2020) High-performance CRISPR-Cas12a genome editing for combinatorial genetic screening. Nature communications, 11(1), 3455.

Saenz DT, et al. (2020) Mechanistic basis and efficacy of targeting the ?-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors. Blood, 135(15), 1255.

Prigent A, et al. (2019) Acute inflammation down-regulates alpha-synuclein expression in enteric neurons. Journal of neurochemistry, 148(6), 746.

Lin KH, et al. (2019) Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity. Cell metabolism, 29(5), 1217.

Celik H, et al. (2018) JARID2 Functions as a Tumor Suppressor in Myeloid Neoplasms by Repressing Self-Renewal in Hematopoietic Progenitor Cells. Cancer cell, 34(5), 741.

Tarumoto Y, et al. (2018) LKB1, Salt-Inducible Kinases, and MEF2C Are Linked Dependencies in Acute Myeloid Leukemia. Molecular cell, 69(6), 1017.

Jin L, et al. (2018) MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. Cancer cell, 34(2), 315.

Chung J, et al. (2017) Erythropoietin signaling regulates heme biosynthesis. eLife, 6.